Cooperative Agreement 2026188

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,656 to Bioparin, LLC to develop biotechnological approaches for expeditious synthesis of heparin-like anticoagulants using engineered microbial cellular factories. The award aims to address challenges in securing reliable sources of animal-derived heparin, a critical medicine for treating thrombosis and other clotting disorders,...

Exopolymer, Inc. received a $648,366 Small Business Innovation Research (SBIR) Project Grant from the Department of Agriculture's National Institute of Food and Agriculture to develop new fermentation-derived biopolymer ingredients. Under this two-year award running from September 2021 to August 2023, Exopolymer will finalize the commercial development of one or more biopolymer products that outperform hyaluronic acid in moisture binding and skin penetration performance. Work will include...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $944,676 to Haima Therapeutics LLC, a woman-owned small business, to develop a novel platelet-inspired nanotechnology to restore hemostasis in patients on antiplatelet agents. The goal is to create a synthetic, donor-independent therapeutic that can effectively restore hemostatic function in traumatic brain injury (TBI) patients taking P2Y12 inhibitors, which...

This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program will support the development of a novel mammalian cell-based nano-biological coating for implantable medical devices at Novaurum Biosciences Incorporated in Somerville, MA. The project aims to address the critical issue of implant-related infections, which cost the U.S. healthcare system over $8.6 billion annually, by creating a biocompatible and...

This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...

Karios Technologies LLC, a for-profit organization, received a $274,954 SBIR Phase I grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel, ready-to-use, large volume delivery system for in situ forming biomaterials. The biomaterials are intended to serve as tissue sealants, scar tissue reducers, and vehicles for drug or cell delivery during surgical procedures. The project aims to transfer a proprietary biomaterial...

Hermes Life Sciences LTD received a $1,126,590 cooperative agreement award from the National Science Foundation under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to support the SBIR PHASE II: BLOOD-PLASMA SEPARATION FOR POINT-OF-CARE DIAGNOSTIC TESTING project. The funding period is from August 1, 2021 through January 31, 2024. Under this cooperative agreement, Hermes Life Sciences LTD will develop technologies for blood-plasma separation to enable point-of-care...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,989,548.00 to Cerulean Scientific Inc., a small disadvantaged business in Durham, North Carolina, to develop a slippery, omniphobic coating for peripheral vascular grafts (PVGs). The goal is to investigate the ability of the tethered liquid perfluorocarbon (TLP) coating to resist occlusion, thrombus formation, and biofilm formation on PVGs, which are a common...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to establish proof-of-concept for applying targeted fluorination to enhance the pharmacological properties of recombinant protein therapeutics (RPTs) for the treatment of inborn errors of metabolism. The $306,873 award to Halide Biologics, Inc. will fund the development of novel RPT variants with...

This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...